|
|
|||
| |||||||||||||||||||||||||||||||||||||
The conclusion by Fisher et al. that "treatment with the TNFR:Fc fusion protein does not reduce mortality, and higher doses appear to be associated with increased mortality" is valid given the results of their study. However, I am concerned that only 4 percent of all the patients
References
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved. |